Proposal for Navitoclax (ABT-263, Selleckchem S1001)

Overview of Therapeutic Candidate:
Navitoclax, also known as ABT-263 (Selleckchem S1001), is an orally bioavailable small-molecule that belongs to the class of BH3 mimetics. This compound was originally discovered and synthesized through targeted medicinal chemistry programs aimed at inhibiting anti-apoptotic members of the B-cell lymphoma 2 (BCL-2) family, including BCL-2, BCL-xL, and BCL-W. Its design was based on the structural understanding of the interaction between anti-apoptotic proteins and BH3-only ligands, with the goal of mimicking the natural pro-apoptotic signals that regulate mitochondrial membrane permeabilization and cell death (Anuar et al., 2020). BH3 mimetics like Navitoclax were initially developed for oncologic indications to trigger apoptosis in cancer cells that rely on BCL-2 family proteins for survival. These small molecules have been extensively studied in hematologic malignancies and select solid tumors – notably small cell lung cancer and chronic lymphocytic leukemia – where they have demonstrated potent pro-apoptotic effects (Anuar et al., 2020; ClinicalTrials.gov, n.d.). Synthetic modifications and formulation improvements aimed at enhancing oral bioavailability and managing on-target toxicities (e.g., thrombocytopenia due to BCL-xL inhibition) contributed to the evolution of Navitoclax into a well-characterized candidate that has advanced into clinical trials in the oncology realm.

Therapeutic History:
Originally designed as an anticancer agent, Navitoclax has a well-documented therapeutic history in oncology. Early clinical studies demonstrated its ability to induce dose-dependent apoptosis in lymphoid cells, which positioned it as a promising agent for treating relapsed or refractory lymphoid malignancies (AbbVie, 2006). Its mechanism of inducing apoptosis in malignant cells relies on the inhibition of anti-apoptotic BCL-2 family members—a pathway that is similarly exploited to clear senescent cells. Over time, preclinical investigations began to highlight the repurposing potential of Navitoclax beyond oncology. In particular, several studies have identified that senescent cells – including senescent myofibroblasts – accumulate in various fibrotic disorders such as idiopathic pulmonary fibrosis (IPF). These cells exhibit resistance to apoptosis, partly due to elevated expression of anti-apoptotic proteins that are the direct targets of Navitoclax (Anuar et al., 2020). Preclinical work in animal models of lung fibrosis has demonstrated that Navitoclax can effectively induce apoptosis of senescent and apoptosis-resistant myofibroblasts, thereby reducing fibrotic cell burden and mitigating extracellular matrix accumulation (Hernandez-Gonzalez et al., 2023; Lagares et al., 2017). Although its use in IPF has not yet reached broad clinical application, the extensive oncology clinical safety and pharmacokinetic data provide a strong foundation for its repurposing in fibrotic lung diseases (ClinicalTrials.gov, n.d.).

Mechanism of Action:
At the molecular level, Navitoclax operates by binding to the hydrophobic groove of anti-apoptotic BCL-2 family proteins, thereby competitively displacing pro-apoptotic BH3-only proteins, such as BIM. Under normal circumstances, BIM is sequestered by BCL-2 and BCL-xL to prevent the activation of the intrinsic apoptotic pathway. When Navitoclax binds to these proteins, it releases BIM, which then proceeds to activate the multi-domain pro-apoptotic proteins BAX and BAK. These proteins oligomerize in the mitochondrial outer membrane, leading to mitochondrial outer membrane permeabilization, cytochrome c release, activation of caspases, and ultimately programmed cell death (Anuar et al., 2020). In fibrotic lung diseases like IPF, senescent myofibroblasts and certain epithelial cells (notably type II pneumocytes) become resistant to apoptosis due to persistent upregulation of BCL-2 family proteins. By selectively inhibiting these proteins, Navitoclax offers a means to restore apoptotic sensitivity in these cells, effectively reducing their accumulation and the resultant profibrotic secretory phenotype that drives extracellular matrix deposition and tissue remodeling (Anuar et al., 2020; Lagares et al., 2017). Additional research has demonstrated that aside from solely triggering apoptosis, Navitoclax may also modulate other pathways such as attenuating mitochondrial antiviral signaling (MAVS) aggregation in lung epithelial cells, a process contributing to fibrogenesis via damage-associated molecular pattern (DAMP) signaling (Kim et al., 2021; Kim & Shin, 2021). This dual action—senolytic clearance of fibrogenic cells along with modulation of pro-fibrotic innate immune signaling—underscores the potential of Navitoclax to impact multiple facets of IPF pathology.

Expected Effect:
The central hypothesis for repurposing Navitoclax in IPF is predicated on its ability to selectively induce apoptosis in senescent myofibroblasts, thereby reducing the profibrotic cell burden in the lung. In the proposed assays, such as those using 3D collagen gel contraction models, Navitoclax is expected to diminish myofibroblast contractility by eliminating senescent cells that contribute to the pathological stiffening and remodeling of lung tissue (Anuar et al., 2020). Senescent myofibroblasts in IPF are known to secrete a senescence-associated secretory phenotype (SASP) that propagates local inflammation and further activates resident mesenchymal cells, thereby exacerbating extracellular matrix (ECM) deposition. By clearing these cells, Navitoclax is anticipated to interrupt the vicious cycle of fibrogenesis, resulting in decreased collagen synthesis and improved tissue compliance (Hernandez-Gonzalez et al., 2023; Cazzola et al., 2018). Biochemically, this effect is mediated through the robust activation of caspase-3 dependent apoptosis pathways, with subsequent reduction in markers associated with cellular senescence such as p16^INK4a and p21^CIP1/WAF1. Furthermore, preclinical models of pulmonary fibrosis have demonstrated that BH3 mimetics similar to Navitoclax can reverse established fibrotic lesions and improve lung function by restoring the balance between cell survival and cell death in the fibrotic microenvironment (Lagares et al., 2017; Anuar et al., 2020). In addition, studies have shown that selective senolytic activity against fibrosis-driving cells may also lead to modulation of stress pathways such as endothelial reticulum (ER) stress, further facilitating the restoration of normal cell turnover and tissue repair (Le Saux et al., 2024).

Overall Evaluation:
The repurposing of Navitoclax for IPF is supported by a robust body of biomedical, clinical, and biochemical evidence. Strengths of Navitoclax include its well-characterized mechanism of action, which directly addresses a key pathophysiologic component of IPF—namely, the accumulation of apoptosis-resistant, senescent myofibroblasts. Preclinical studies in various models of fibrosis have demonstrated that inhibition of BCL-2 family proteins results in significant reduction of fibrotic markers and reversal of tissue remodeling (Anuar et al., 2020; Lagares et al., 2017). Moreover, Navitoclax’s clinical history in oncology has provided extensive pharmacokinetic and safety data, allowing for a faster translational path when repurposing the drug for non-oncologic indications such as IPF (AbbVie, 2006; Anuar et al., 2020). Its dual capability to induce apoptosis and potentially modulate pro-fibrotic innate immune signaling through effects on MAVS aggregation further enhances its appeal as a candidate with multi-layered effects on lung pathology (Kim et al., 2021; Kim & Shin, 2021).

However, there are important caveats to consider. The known adverse effects observed in oncology trials, such as thrombocytopenia and neutropenia stemming from BCL-xL inhibition, may limit dose escalation or require careful dosing strategies in a chronic disease setting like IPF (Anuar et al., 2020; Cazzola et al., 2018). Furthermore, the timing of drug administration appears critical; studies have shown that early intervention with BH3 mimetics in certain lung injury models may paradoxically exacerbate tissue damage by affecting non-target cell populations, highlighting the need for precise therapeutic windows (Cooley & Redente, 2024; Kim & Shin, 2021). Additionally, while preclinical models – including those using 3D collagen gels and murine transplantation of senescent fibroblasts – consistently show promise, the translation of these results to human IPF pathology remains a considerable challenge due to the complex and heterogeneous nature of the disease (Hernandez-Gonzalez et al., 2023; Anuar et al., 2020).

Overall, the evidence supports the hypothesis that Navitoclax can treat IPF by selectively eliminating senescent myofibroblasts and reducing the fibrotic burden. Its proven ability to induce apoptosis in cells that rely on anti-apoptotic BCL-2 proteins is well-aligned with the cellular pathobiology observed in IPF (Anuar et al., 2020; Lagares et al., 2017). The extensive pharmacologic and clinical data available from oncology studies provide significant advantages in terms of known pharmacokinetics and potential safety management. Nonetheless, the safety profile in chronic fibrotic conditions and the precise optimization of dosing regimens remain the most notable weaknesses and represent key areas for further investigational study. Given these considerations, Navitoclax emerges as a highly promising candidate for repurposing in IPF therapy, provided that forthcoming clinical trials can carefully address its potential toxicities and validate its efficacy in human fibrotic lung tissue (ClinicalTrials.gov, n.d.; Anuar et al., 2020; Lagares et al., 2017).

In summary, the proposed repurposing of Navitoclax for IPF is scientifically compelling and supported by a multifaceted body of evidence drawn from oncology, fibrosis, and senescence research. The therapeutic candidate not only exhibits a well-established mechanism to counter the apoptosis resistance of senescent myofibroblasts but also carries the advantage of extensive preclinical and clinical data that could expedite its translation into the IPF treatment arena. This dual-action of promoting apoptosis while potentially modulating innate immune stress responses provides a strong rational basis for further exploration in clinical trials tailored to fibrotic lung diseases. While challenges remain—particularly concerning safety and optimal treatment windows—the overall evaluation indicates that Navitoclax possesses substantial potential as an innovative, mechanism-based therapeutic approach for patients with idiopathic pulmonary fibrosis.

References:

AbbVie. (2006). A study of ABT-263 in subjects with relapsed or refractory lymphoid malignancies. ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT00406809

Anuar, N. N. M., Nor Hisam, N. S., Liew, S. L., & Ugusman, A. (2020). Clinical review: Navitoclax as a pro-apoptotic and anti-fibrotic agent. Frontiers in Pharmacology, 11, Article 564108. https://doi.org/10.3389/fphar.2020.564108

Cazzola, M., Matera, M. G., Rogliani, P., & Calzetta, L. (2018). Senolytic drugs in respiratory medicine: Is it an appropriate therapeutic approach? Expert Opinion on Investigational Drugs, 27(7), 573–581. https://doi.org/10.1080/13543784.2018.1492548

ClinicalTrials.gov. (n.d.). Search for Navitoclax OR ABT-263 OR BCL-2 inhibitor AND (idiopathic pulmonary fibrosis OR lung fibrosis OR fibrotic lung disease). https://clinicaltrials.gov/ct2/results?cond=&term=Navitoclax+OR+ABT-263+OR+BCL-2+inhibitor+AND+%28idiopathic+pulmonary+fibrosis+OR+lung+fibrosis+OR+fibrotic+lung+disease%29

Cooley, J. C., & Redente, E. F. (2024). Getting the timing right: Controlling bcl-2 inhibition as an antifibrotic therapy. American Journal of Respiratory Cell and Molecular Biology, 70, 231–232. https://doi.org/10.1165/rcmb.2023-0436ed

Hernandez-Gonzalez, F., Prats, N., Ramponi, V., López-Domínguez, J. A., Meyer, K., Aguilera, M., Muñoz Martín, M. I., Martínez, D., Agustí, A., Faner, R., Sellarés, J., Pietrocola, F., & Serrano, M. (2023). Human senescent fibroblasts trigger progressive lung fibrosis in mice. Aging, 15, 6641–6657. https://doi.org/10.18632/aging.204825

Kim, S.-H., & Shin, H. J. (2021). Mavs is crucial for the development of pulmonary fibrosis and is inhibited by proapoptotic BH3 mimetics [Unpublished manuscript].

Kim, S.-H., Lee, J. Y., Yoon, C. M., Shin, H. J., Lee, S. W., Rosas, I., Herzog, E., Dela Cruz, C. S., Kaminski, N., & Kang, M.-J. (2021). Mitochondrial antiviral signaling protein is crucial for the development of pulmonary fibrosis. European Respiratory Journal, 57, 2000652. https://doi.org/10.1183/13993003.00652-2020

Lagares, D., Santos, A., Grasberger, P. E., Liu, F., Probst, C. K., Rahimi, R. A., Sakai, N., Kuehl, T., Ryan, J., Bhola, P., Montero, J., Kapoor, M., Baron, M., Varelas, X., Tschumperlin, D. J., Letai, A., & Tager, A. M. (2017). Targeted apoptosis of myofibroblasts with the BH3 mimetic ABT-263 reverses established fibrosis. Science Translational Medicine, 9(420), eaal3765. https://doi.org/10.1126/scitranslmed.aal3765

Le Saux, C. J., Ho, T. C., Brumwell, A. M., Kathiriya, J. J., Wei, Y., Hughes, J. B., Garakani, K., Atabai, K., Auyeung, V. C., Papa, F. R., & Chapman, H. A. (2024). Bcl-2 modulates IRE1α activation to attenuate endoplasmic reticulum stress and pulmonary fibrosis. American Journal of Respiratory Cell and Molecular Biology, 70, 247–258. https://doi.org/10.1165/rcmb.2023-0109oc
